NCT04376528

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 89 (estimated)
• Sponsor: West China Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome induced by mycophenolate mofetil versus cyclosporin A

Conditions

• Hepatitis, Autoimmune
• Primary Biliary Cholangitis
• Immunosuppression

Interventions

Type	Name	Description
DRUG	Cyclosporin A	Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with cyclosporin A)
DRUG	Mycophenolate Mofetil	Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with mycophenolate mofetil )

Timeline

• Start date: 2021-06-16
• Primary completion: 2021-12-30
• Completion: 2021-12-30
• First posted: 2020-05-06
• Last updated: 2021-06-22

Locations

1 site across 1 country: China